tbuckley/cabot-search huggingface dataset:
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Previously Untreated Multiple Myeloma (MM).
Authors: James R. Berenson, Ori Yellin, Ravi Patel, Chien-Shing Chen, Ralph Vincent Boccia, Donald Colbourn, Honghao (Hank) Yang, Varun Gupta, George F. Geils, Youram Nassir, Jacqueline Hilger, Regina A. Swift
Journal: Blood (2009)
Acute Graft Versus Host Disease after Nonmyeloablative Allogeneic Stem Cell Transplantation with Low-Dose TBI, Fludarabine and Antithymocyte Globulin (ATG).
Authors: Celia L. Grosskreutz, Ronald Egan, Eileen Scigliano, Steven M. Fruchtman, Luis M. Isola
Journal: Blood (2004)
AB0247 A New Disease Activity Biomarker Alternative To CRP under Tocilizumab Therapy for Rheumatoid Arthritis via Peptidomic Analysis
Authors: T. Seno, D. Nonaka, M. Kohno, H. Sofue, A. Kasahara, R. Sagawa, T. Kida, Y. Kukida, K. Fujioka, W. Fujii, K. Murakami, L.-J. Lee, K. Tanaka, Y. Kawahito
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Tocilizumab, anti-IL-6 receptor monoclonal antibody, is widely used for patients with rheumatoid arthritis. IL-6 is essential for production of C-reactive protein (CRP). Tocilizumab fully inhibit the production of CRP. Therefore, we have difficulty in objective assessment of infection and disease activity because the level of CRP is suppressed under tocilizumab therapy. The development of new biomarker alternative to CRP is needed for daily practice. <h3>Objectives</h3> To discover new biomarkers alternative to CRP under tocilizumab therapy for rheumatoid arthritis. <h3>Methods</h3> We registered patients with rheumatoid arthritis treated with tocilizumab. We collected serum samples from those patients at baseline, 4 weeks after the first tocilizumab administration when patient9s CRP level is almost normal, and 1 year later. And we measured CRP, ESR and clinical disease activity index (CDAI) score.Serum peptidomic analysis was conducted by newly-established one-step direct transfer technology (BLOTCHIP-MS analysis), a rapid quantitative technology for peptidomic analysis. All sample measurements were repeated four times. Statistical analyses of MS spectral data were conducted using ClinProTools version 2.2 (Bruker Daltonics). <h3>Results</h3> We registered 14 patients and their background is shown in Table 1. The levels of CRP were 1.16±0.99 mg/dl at baseline, 0.02±0.01 mg/dl at 4 weeks and 0.01±0.01mg/dl at 1 year, respectively. Their CDAI score were 22±9.2 at baseline, 15±8.9 at 4 weeks and 3±2.6 at 1 year, respectively. CRP titer decreased to almost normal level at 4 weeks regardless whether CDAI score did not fully decrease. We detect 6 biomarkers, named as PRSJ01 to PRSJ06, by the peptidomic analysis (Table 2). The AUC of diagnostic value of these markers is from 0.742 to 0.858. For example, the level of PRSJ06 significantly decreased 4 weeks (Wilcoxon singed-rank test, <i>p</i>=0.02) and 1 year (Wilcoxon singed-rank test, <i>p</i>=0.003) after first tocilizumab administration (Figure 1). and it was inversely-correlated with CDAI score. <h3>Conclusions</h3> We detect new disease activity biomarkers alternative to CRP under tocilizumab therapy for rheumatoid arthritis. It is useful for exact evaluation of disease activity and infection during tocilizumab therapy. <h3>Disclosure of Interest</h3> None declared
Comparable Immune Reconstitution Achieved Following Unmanipulated HLA-Mismatched/Haploidentical Transplantation and HLA-Identical Sibling Transplantation
Authors: Ying-Jun Chang, Xiao Jun Huang, Xiang-Yu Zhao, Ming-Rui Huo, Lan-Ping Xu, Dai-Hong Liu, Kai-Yan Liu
Journal: Blood (2010)
Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia
Authors: Stephen J. Schuster, Chitra M Hosing, Elizabeth J Shpall, Bruce L Levine, Nicole A. Aqui, Elise A. Chong, Jakub Svoboda, Amanda Gordon, John D McMannis, Doyle Bosque, Julio Cotte, Andrea L Brennan, Zhaohui Zheng, Leah Leinbach, YinYan Xu, Elizabeth Veloso, William Decker, Catherine M. Bollard, Michael J Keating, Carl H. June
Journal: Blood (2011)
CBT4BN: A Randomized Controlled Trial of Online Chat and Face-to-Face Group Therapy for Bulimia Nervosa
Authors: Stephanie C. Zerwas, Hunna J. Watson, Sara M. Hofmeier, Michele D. Levine, Robert M. Hamer, Ross D. Crosby, Cristin D. Runfola, Christine M. Peat, Jennifer R. Shapiro, Benjamin Zimmer, Markus Moessner, Hans Kordy, Marsha D. Marcus, Cynthia M. Bulik
Journal: Psychotherapy and Psychosomatics (2016)

Although cognitive-behavioral therapy (CBT) represents the first-line evidence-based psychotherapy for bulimia nervosa (BN), most individuals seeking treatment do not have access to this specialized intervention. We compared an Internet-based manualized version of CBT group therapy for BN conducted via a therapeutic chat group (CBT4BN) to the same treatment conducted via a traditional face-to-face group therapy (CBTF2F).In a two-site, randomized, controlled noninferiority trial, we tested the hypothesis that CBT4BN would not be inferior to CBTF2F. A total of 179 adult patients with BN (2.6% males) received up to 16 sessions of group CBT over 20 weeks in either CBT4BN or CBTF2F, and outcomes were compared at the end of treatment and at the 12-month follow-up.At the end of treatment, CBT4BN was inferior to CBTF2F in producing abstinence from binge eating and purging. However, by the 12-month follow-up, CBT4BN was mostly not inferior to CBTF2F. Participants in the CBT4BN condition, but not CBTF2F, continued to reduce their binge-eating and purging frequency from the end of treatment to the 12-month follow-up.CBT delivered online in a group chat format appears to be an efficacious treatment for BN, although the trajectory of recovery may be slower than face-to-face group therapy. Online chat groups may increase accessibility of treatment and represent a cost-effective approach to service delivery. However, barriers in service delivery such as state-specific license and ethical guidelines for online therapists need to be addressed.
Integration of Novel Agents into the Care of Patients with Multiple Myeloma
Authors: Robert Z. Orlowski, Sagar Lonial
Journal: Clinical Cancer Research (2016)

Abstract The pace of therapeutic drug development in multiple myeloma has reached unprecedented levels, with five regulatory approvals for relapsed and/or refractory disease of either new drugs or new drug regimens in 2015, one already in 2016, and still others anticipated. This has provided a wide array of options to be considered by patients and their health care providers in the event of relapse after or progression on front-line therapy. Most of these agents are currently being evaluated in earlier patient populations, including as parts of induction, consolidation, and maintenance therapy approaches, where their benefits may be even greater. Moreover, additional randomized studies have been completed with our previous stable of novel agents that inform their use in these settings as well. In the current contribution to this CCR Focus on multiple myeloma, we will present an overview of some of the key recent data that have supported the addition of these new therapeutics to our armamentarium against multiple myeloma. Also, we will provide some guidelines about possible best practices in applying these regimens and attempt to extrapolate how they will be used as parts of our future standards of care. Clin Cancer Res; 22(22); 5443–52. ©2016 AACR. See all articles in this CCR Focus section, “Multiple Myeloma: Multiplying Therapies.”
Tacrolimus/Methotrexate (MTX) Versus Cyclosprorine/MTX for Graft-Versus-Host Disease (GVHD) Prophylaxis in Patients with Severe Aplastic Anemia (SAA) Who Received Marrow Transplantation from Unrelated Donors: Results of a Matched Pair Analysis.
Authors: Seiji Kojima, Hiromasa Yabe, Koji Kato, Hisato Kigasawa, Hisashi Sakamaki, Masahiro Tsuchida, Shunichi Kato, Yasuo Morishima, Yoshihisa Kodera
Journal: Blood (2005)
Diffuse Large B Cell Lymphoma (DLBCL) infiltrating T Cells Display an Activated and Exhausted Status and Are Inhibited By Ligands of Cosignaling Receptors Including PD-L1, PD-L2 and CD80 Expressed By Most DLBCL in Situ
Authors: Daniel Olive, Kieu Suong Le, Mikael Roussel, Florence Broussais, Imane Azzaoui, Delphine Rossille, Reda Bouabdallah, Thierry Fest, Luc Xerri, Thierry Lamy, Céline Pangault
Journal: Blood (2014)
A Recombinant Thrombomodulin Improves Haemostatic Disturbance and Inflammation in Setpic Patients with DIC
Authors: Noritaka Yada, Kenji Nishio, Hidetada Fukushima, Tadahiko Seki, Yasuyuki Urizono, Michiaki Hata, Hideki Asai, Masaaki Doi, Hideto Matsui, Mitsuhiko Sugimoto, Kazuo Okuchi
Journal: Blood (2011)
PTH-159 Alcohol Detoxification Drug Chart Audit
Authors: V Galanakis, K Lambert, S Williams
Journal: Gut (2016)

<h3>Introduction</h3> Alcohol misuse is a rising problem and alcohol related admissions are common. Alcohol detoxification (DETOX) regimes vary and frequently confuse the prescribers and nurses leading to administration errors, compromising the patient’s care and possibly contributing to early readmissions, by not achieving maximum detoxification. In order to improve that, we have developed and trialled a chlordiazepoxide prescription drug chart in our emergency assessment unit. Following the introduction of the chart there was a significant reduction in prescription and administration errors. The chart is now the standard means of prescribing alcohol detoxification regimes in our hospital. <h3>Methods</h3> We reviewed 43 patient’s notes with respect to chlordiazepoxide prescription and identified errors in the prescribed DETOX schedule, timing and missed doses. We then developed a drug chart, which was intended to guide the clinician to assess the severity of alcohol dependence using the severity of alcohol dependency questionnaire (SADQ) and then prescribing the correct chlordiazepoxide schedule, bypassing possible prescription errors. We then reviewed 56 medical notes following the introduction of the drug chart and statistically compared the prescription errors (2 population proportion test). We also compared the median total chlordiazepoxide dose given in milligrams and the duration of regimes in days (t test for 2 independent means) in order to identify a possible impact of those elements to alcohol related early (&lt; 28 days) re-admissions. <h3>Results</h3> The chart has led to significant (p &lt; 0.05) reduction of wrong schedule and timing prescriptions, as well as significant (p &lt; 0.05) increase in SADQ score calculation. There was no significant reduction in missed doses. It was also noted that the average length (days) and milligrams of detoxification regimes were inversely proportional to the risk of early re-admission, although these results were not statistically significant, suggesting that the chart might contribute to a reduction in early readmission by ensuring adequate detoxification. <h3>Conclusion</h3> Our experience suggests that DETOX regimes can be cumbersome to prescribe leading to prescription errors, thus compromising patient’s care. The idea of introducing a chlordiazepoxide drug chart was to achieve better care for these patients, by simplifying the prescription process. Our results imply that this was achieved with a suggestion that early readmissions were reduced. The chart is now established as part of alcohol DETOX management at Ipswich Hospital. <h3>References</h3> 1 Alcohol Misuse Management Guideline Version 1.0 – 2014, Ipswich Hospital 2 Emergency Medicine Journal, 2014. 3 Alcohol use disorders: sample chlordiazepoxide dosing regimens for use in managing alcohol withdrawal, NICE Feb. 2010. 4 Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence, NICE 2011. <h3>Disclosure of Interest</h3> None Declared
The Antimalarial Agent Artesunate Overcomes Bortezomib Resistance in Myeloma Cell Lines Through Non-Caspase Mediated Apoptosis
Authors: Xenofon Papanikolaou, Ruslana Tytarenko, Tarun K. Garg, Sarah K. Johnson, Erming Tian, Senu Apewokin, Bart Barlogie, Joshua Epstein, Christoph Heuck
Journal: Blood (2012)
Delivery of Flightless I Neutralizing Antibody from Porous Silicon Nanoparticles Improves Wound Healing in Diabetic Mice
Authors: Christopher T. Turner, Steven J. P. McInnes, Elizabeth Melville, Allison J. Cowin, Nicolas H. Voelcker
Journal: Advanced Healthcare Materials (2016)

Flightless I (Flii) is elevated in human chronic wounds and is a negative regulator of wound repair. Decreasing its activity improves healing responses. Flii neutralizing antibodies (FnAbs) decrease Flii activity in vivo and hold significant promise as healing agents. However, to avoid the need for repeated application in a clinical setting and to protect the therapeutic antibody from the hostile environment of the wound, suitable delivery vehicles are required. In this study, the use of porous silicon nanoparticles (pSi NPs) is demonstrated for the controlled release of FnAb to diabetic wounds. We achieve FnAb loading regimens exceeding 250 µg antibody per mg of vehicle. FnAb-loaded pSi NPs increase keratinocyte proliferation and enhance migration in scratch wound assays. Release studies confirm the functionality of the FnAb in terms of Flii binding. Using a streptozotocin-induced model of diabetic wound healing, a significant improvement in healing is observed for mice treated with FnAb-loaded pSi NPs compared to controls, including FnAb alone. FnAb-loaded pSi NPs treated with proteases show intact and functional antibody for up to 7 d post-treatment, suggesting protection of the antibodies from proteolytic degradation in wound fluid. pSi NPs may therefore enable new therapeutic approaches for the treatment of diabetic ulcers.
Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Authors: Barbara Pro, Ranjana H Advani, Pauline Brice, Nancy L Bartlett, Joseph D Rosenblatt, Tim Illidge, Jeffrey Matous, Radhakrishnan Ramchandren, Michelle A Fanale, Joseph M. Connors, Keenan Fenton, Dirk Huebner, Juan Pinelli, Andrei R. Shustov
Journal: Blood (2016)
AB0808 Comorbidities Associated with Gout Are Also Common in Sub-Saharan Africa than in Developed Countries: A Cross-Sectional Study in Cameroon: Table 1.
Authors: F. Kemta Lekpa, M.S. Doualla, M. Singwe-Ngandeu, H. Namme Luma
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Comorbidities associated with gout are frequently described in developed countries. Data are scarce in sub-Saharan Africa. <h3>Objectives</h3> To identify the main comorbidities associated with gout in Cameroon, Central Africa. <h3>Methods</h3> We performed a cross-sectional study on patients seen in the Rheumatology department of the Douala General Hospital, Douala, Cameroon, between January 2004 and December 2013. We have included the records of patients with diagnosis of gout according to ACR criteria 1977. The main comorbidities of gouty patients were recorded. A p&lt;0.05 was considered statistically significant. <h3>Results</h3> We included 511 patients (415 men and 96 women). The mean age was 55.9±10.8 years. The main comorbidities associated with gout in our study are summarized in Table 1. Metabolic syndrome was present in 101 patients (19.7%). Chronic kidney disease and dyslipidemia were more frequent in rural areas while the obesity and hypertension were more frequent in urban areas (p&lt;0.05) [Table 2]. The association between gout and components of metabolic syndrome were all significant (p&lt;0.001), particularly for obesity and dyslipidemia in men and hypertension and diabetes in women. <h3>Conclusions</h3> Comorbidities are common in Cameroonians with gout like in developed countries. These data should encourage seeking and treating gastrointestinal adverse events and cardiovascular risk factors in gouty patients to reduce morbidity and mortality linked to gout. <h3>Disclosure of Interest</h3> None declared
Compassionate Use of Nilotinib (AMN107) in Mexican Patients with Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib.
Authors: Manuel Ayala, Rafael Hurtado, Kevin Nacho, Norma Tapia, Martha Alvarado, Alvaro Aguayo, Sergio Cleto, Yolanda Lugo, Gustavo Reyes, Pablo Vargas, Angel Herrera, Luis Antonio Meillon
Journal: Blood (2007)
Arginase Inhibitors: A Rational Approach Over One Century
Authors: Marc Pudlo, Céline Demougeot, Corine Girard‐Thernier
Journal: Medicinal Research Reviews (2016)

Abstract Arginase (EC 3.5.3.1) is the bimanganese enzyme that converts L‐arginine into ornithine and urea. This enzyme was discovered more than a century ago and early α‐amino acids were identified as weak inhibitors. It was only during the 90s, after nitric oxide (NO) was reported as one of the most important biological mediators and when tight interrelation of arginase and NO synthase was found, that the development of arginase inhibitors was accelerated. The regulation of arginase activity by the N ‐hydroxy‐L‐arginine (3, NOHA) intermediate of the NO synthesis was the starting point of the N ‐hydroxy‐nor‐arginine (21, nor‐NOHA) that proved to be the first micromolar inhibitor. The previously known manganese and arginase binding by borate inspired the 2( S )‐amino‐6‐boronohexanoic acid (39, ABH) and S ‐(2‐boronoethyl)‐L‐cysteine (40, BEC) now both considered as reference compounds in arginase inhibition. The high‐resolution crystal structure of arginase and molecular modeling has rendered possible the recent design of (53) the strongest α,α‐disubstituted derivatives of ABH. Simultaneously, traditional medicinal plants have contributed as a source of molecular diversity to the discovery of arginase inhibitors. This rational, step‐by‐step approach serves as guide in the present review where emphasis is placed on structure activity relationships. Highlights exhaustive review on arginase inhibitors highlight is made on rational approach to conception and structure activity relationships evaluation model is systematically mentioned with results.
SP0143 Ultrasound for Diagnosing Inflammatory versus Mechanical Midfoot Pain and Relevant Guided Interventions with Demonstration
Authors: H. Siddle
Journal: Annals of the Rheumatic Diseases (2016)

The midfoot is a relatively unknown entity and difficult to examine clinically. Recent inflammatory arthritis studies have demonstrated that patients in disease remission may still have active disease in those residual joints not included in commonly used disease activity assessments. Osteoarthritis (OA) of the midfoot has previously been reported as being relatively uncommon (prevalence of 3.8%) however recent studies have highlighted that medial midfoot OA is more prevalent than previously described. Halstead et al (2015) reported changes most frequently in the cuneiform-second metatarsal joint (73%), followed by the naviculo-medial cuneiform joint (51%), the cuneiform-first metatarsal joint (46%) and the talo-navicular joint (24%), with patients indicating pain to the dorsal midfoot area. The midfoot is a complex structure and frequently undertreated. Differentiating between inflammatory and mechanical disease in the midfoot will enable the clinician to direct their treatment strategies more appropriately. Ultrasound imaging offers the clinician the opportunity to differentiate between joints that require treatment with mechanical interventions such as orthoses and footwear, and those that may also require local treatment of inflammatory disease which may include a guided steroid injection to improve the clinical outcome. <h3>Disclosure of Interest</h3> None declared
Erythropoietin Treatment Is Associated with Augmented Immune Response to the Influenza Vaccine in Hematologic Patients.
Authors: Howard S Oster, Sara Prutchi-Sagiv, Ora Halutz, Nataliya Golishevski, Moshe Binyamin, Ruth Orkin, Michael Hoffman, Drorit Neumann, Moshe Mittelman
Journal: Blood (2009)
FRI0554 Poverty Modifies The Effect of Race on Total Knee Arthroplasty Outcomes: Table 1.
Authors: S.M. Goodman, M.L. Parks, M.H. Bogardus, M. Zhang, J.T. Nguyen, Y.-Y. Lee, M.P. Figgie, L.A. Mandl, A.R. Bass
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Race is an important predictor of total knee arthroplasty (TKA) outcomes in the United States; however analyses of race can be confounded by socioeconomic factors. <h3>Objectives</h3> To analyze the interaction between race and community poverty as it effects patient reported outcomes after TKA. <h3>Methods</h3> We identified all patients undergoing TKA enrolled in a hospital based registry between 2007 and 2011, living in three adjacent states. Using geocoding we linked individual-level registry data including WOMAC pain and function to U.S. census tracts (CT) data. We constructed a multivariate linear mixed effect model within multilevel frameworks to assess the interaction between race and CT poverty on 2-year WOMAC outcomes. <h3>Results</h3> Of 4225 TKA patients, 194 (4.6%) were black. Baseline WOMAC scores were statistically but not clinically significantly worse for blacks than for whites (WOMAC Pain 49 vs. 55, p&lt;0.0001; WOMAC Function 47 vs. 54, p&lt;0.0001; 100=best). Fewer blacks had a college education or above (45% vs. 62%, p&lt;0.0001), and blacks had higher BMI (33 vs. 30, p&lt;0.001) and more comorbidities than whites (44% &gt;1 comorbidity vs. 27%, p&lt;0.0001). More blacks lived in high poverty neighborhoods (37% vs. 3.5%, p&lt;0.0001). Controlling for multiple potential confounders, our model demonstrated that whites and blacks from census tracts with &lt;10% poverty have similar 2-year WOMAC scores. With increasing community poverty, pain and function worsened; from census tracts with &gt;50% poverty blacks had clinically meaningful worse pain and function compared to whites (Table 1). <h3>Conclusions</h3> We have found a significant differential effect of poverty on 2-year outcomes after TKA when stratified by race. Overall WOMAC scores are minimally but not significantly worse for blacks than whites. However, while outcomes among whites do not vary much between high and low poverty census tracts, the effect of high poverty levels was disproportionally associated with worse TKA outcomes among black Americans. Since a higher proportion of blacks live in high poverty areas, this finding has important implications. Efforts to improve TKA outcomes among U.S. blacks will need to investigate both the impact of individual patient-level factors and community-level poverty. <h3>Disclosure of Interest</h3> None declared
Type II HMG-CoA Reductase Inhibitors (Statins) Provide Acute-Graft-Versus-Host Disease Protection by Th-2 Cytokine Induction While Sparing Graft-Versus-Leukemia Activity.
Authors: Robert Zeiser, Sawsan Youssef, Jeanette Baker, Lawrence Steinman, Robert Negrin
Journal: Blood (2006)
Abstract 2370: Brain Natriuretic Peptide Enhances Adiponectin Production in Adipocytes
Authors: Osamu Tsukamoto, Masanori Asakura, Tetsuo Minamino, Jiyoong Kim, Hiroshi Asanuma, Ichiro Kishimoto, Masafumi Kitakaze
Journal: Circulation (2006)

Background. Adiponectin is a circulating adipose-derived cytokine that provides cardiovascular protection as well as anti-diabetic actions. Although adiponectin is down-regulated in patients with m...
Differential Impact of Relative Dose-Intensity Reductions (DIR) in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP21 or R-CHOP14
Authors: Leyre Bento, Francesc Garcia, Antonia Maria Bautista-Gili, Blanca Sanchez, Lucia Garcia, Eva Gimeno, Jordi Martinez-serra, Mariana Ferraro, Raquel Del campo, Javier Vercher, Miguel Scaff, Ana Pacheco, Florencia Garcia, Rafael Ramos, Carmen Ballester, Juan Besalduch, Joan Bargay, Antonio Salar, Antonio Gutierrez
Journal: Blood (2014)
CXCR7 Participates in Chemotaxis and Homing Mediated By CXCL12
Authors: Rita de Cassia Carvalho Melo, Juliana M. Xavier-Ferrucio, Lauremilia Ricon, Karla Priscila Vieira Vieira Ferro, Carolina L. Bigarella, Gilberto C. Franchi, Alexandre Nowill, Sara Teresinha Olalla Saad
Journal: Blood (2015)